Sailaja Kesiraju
Research Subjects
Sailaja Kesiraju has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
S. Sahariah
Transimmun- Transplantation Immunology and Research Centre, Somajiguda, Hyderabad, Andhra Pradesh 500082 India
3 shared publicationsPurna Paritala
Department of Nephrology and Transplantation, Krishna Institute of Medical Sciences, Hyderabad, India
2 shared publicationsUma Maheswara Rao Ch
Kidney Transplant Unit, Mahavir Hospital and Research Center, AC Guards, Hyderabad, India
2 shared publicationsPraneeth Srikanti
Microsoft India (R&D) Ltd, Hyderabad, India
1 shared publicationSreedhar Reddy
Department of Nephrology and Transplantation, Krishna Institute of Medical Sciences, Hyderabad, India
1 shared publicationV. S. Reddy
Department of Nephrology and Transplantation, Krishna Institute of Medical Sciences, Hyderabad, India
1 shared publication
Latest Publications
- 24 August 2017
- Published by Springer Nature in VirusDisease
- Vol. 28 (3) , 233-241
Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends
Prevalence of hepatitis C infection, which is associated with mortality and morbidity, is higher in chronic kidney disease patients on hemodialysis and transplant recipients when compared to non HCV infected patients. In addition to the conventional risk factors, HCV infection maybe an additional risk factor in the development of chronic kidney disease. HCV causes adverse effects leading to the poor long term outcome in renal transplant recipients; hepatitis C infection can cause both hepatic as well as extra hepatic complications. Prior evaluation and management of HCV infection is recommended for better long term outcome as there are chances of higher rejection rates with HCV treatment. However transplantation is not contraindicated in those patients who cannot be treated prior to the transplantation as patient survival is better when compared to dialysis patients. Kidney Disease Outcome Quality Initiative Clinical Practice Guidelines recommend interferon based therapy only when there is a rapid worsening of HCV related hepatic injury in transplant recipients. HCV treatment has been improved by the addition of direct acting antiviral, protease inhibitors and polymerase inhibitors. Combination therapies are showing improved sustained virological response rates. NS3-4A protease inhibitors, nucleotidic/nucleosidic NS5A and NS5B polymerase inhibitors are promising treatments which are under trials with different combinations. The focus of this review is to evaluate and optimize the treatment options of co-existing HCV infection in renal transplant recipients and discuss more promising alternative treatment regimen.
- 24 August 2017
- Published by Springer Nature in VirusDisease
- Vol. 28 (3) , 233-241
Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends
Prevalence of hepatitis C infection, which is associated with mortality and morbidity, is higher in chronic kidney disease patients on hemodialysis and transplant recipients when compared to non HCV infected patients. In addition to the conventional risk factors, HCV infection maybe an additional risk factor in the development of chronic kidney disease. HCV causes adverse effects leading to the poor long term outcome in renal transplant recipients; hepatitis C infection can cause both hepatic as well as extra hepatic complications. Prior evaluation and management of HCV infection is recommended for better long term outcome as there are chances of higher rejection rates with HCV treatment. However transplantation is not contraindicated in those patients who cannot be treated prior to the transplantation as patient survival is better when compared to dialysis patients. Kidney Disease Outcome Quality Initiative Clinical Practice Guidelines recommend interferon based therapy only when there is a rapid worsening of HCV related hepatic injury in transplant recipients. HCV treatment has been improved by the addition of direct acting antiviral, protease inhibitors and polymerase inhibitors. Combination therapies are showing improved sustained virological response rates. NS3-4A protease inhibitors, nucleotidic/nucleosidic NS5A and NS5B polymerase inhibitors are promising treatments which are under trials with different combinations. The focus of this review is to evaluate and optimize the treatment options of co-existing HCV infection in renal transplant recipients and discuss more promising alternative treatment regimen.
- 22 December 2015
- Published by Springer Nature in Immunologic Research
- Vol. 64 (3) , 791-794
Unexplained post-renal transplant tolerance: a case report
- 22 December 2015
- Published by Springer Nature in Immunologic Research
- Vol. 64 (3) , 791-794
Unexplained post-renal transplant tolerance: a case report
- 1 January 2014
- Published by Elsevier in Transplant Immunology
- Vol. 30 (1) , 52-58
New onset of diabetes after transplantation — An overview of epidemiology, mechanism of development and diagnosis
- 1 January 2014
- Published by Elsevier in Transplant Immunology
- Vol. 30 (1) , 52-58
New onset of diabetes after transplantation — An overview of epidemiology, mechanism of development and diagnosis